Interestingly improved outcome for the bortezomib treatment is associated with increased JUN or Egr1 expression, while JUN or EGR1 knockdown increases the resistance of myeloma cells against bortezomib (Chen et al., 2010). This evidence concerns the gene EGR1 and plasma cell myeloma.